HRC 201

Drug Profile

HRC 201

Alternative Names: HRC-201

Latest Information Update: 05 Sep 2007

Price : $50

At a glance

  • Originator Hemosol Corp
  • Developer Hemosol Corp (CEASED)
  • Class Haemoglobins; Radiopharmaceutical diagnostics
  • Mechanism of Action Magnetic resonance imaging enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Liver metastases

Most Recent Events

  • 02 Feb 2004 Preclinical trials in Liver metastases (diagnosis) in Canada (unspecified route)
  • 02 Feb 2004 HCR 201 is available for licensing (http://www.hrc.hemosol.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top